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Abstract
Introduction: Although a full understanding of the role of sleep is debated, it is
widely accepted that sleep is important for recovery from heavy exercise. Recent research
suggests that sleep restriction (SR) may negatively impact recovery and subsequent
performance. It is unknown if caffeine supplementation mitigates this performance
decrement. Our objective was to investigate the effect of caffeine supplementation on
exercise performance following one night of SR in trained cyclists.
Methods: Subjects (n=10) completed a 3-km time trial (TT) and an exhaustive bout
of exercise in the evening (EX1), then returned to repeat the TT the following morning
(EX2). Exercise trials were separated by a full night of sleep (FULL) or a night of restricted
sleep (SR). Perceived fatigue was also assessed prior to EX2. Caffeine (CAF) or placebo
(PLA) treatments were given before the start of EX2. A randomly counterbalanced, double
blind, placebo controlled design was used to compare the effects of four different treatment
conditions: FULL/PLA, SR/PLA, FULL/CAF, SR/CAF.
Results: Data were analyzed using magnitude-based inferences to compare
differences in EX2 performances only. Power output was ‘possibly’ greater (0.9 ± 3.6%)
following SR/PLA compared to FULL/PLA. Power output was ‘likely’ higher (5.5 ± 4.8%)
following SR/CAF compared with SR/PLA. Perceived fatigue was rank ordered as 1)
SR/PLA, 2) SR/CAF, 3) FULL/PLA, 4) FULL/CAF. Specifically, CAF ‘very likely’
reduced perceived fatigue following SR compared to SR PLA, but remained ‘likely’ higher
than FULL/CAF.
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Conclusion: These data show that caffeine has the ability to mitigate performance
decrements resulting from a single night of SR following heavy exercise. Caffeine also
prevented increases in perceived fatigue following SR.

Keywords: sleep restriction, caffeine, cycling, recovery
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Chapter 1
Introduction

Though a full understanding of the importance of sleep has yet to be clearly
explained, sleep is required for optimal physiological function. Therefore, it is widely
recommended that adults sleep 7 to 9 hours a night. However, much of the population falls
short of these guidelines (18, 60). The most recent poll conducted by the National Sleep
Foundation found that 40% of respondents acquired less than 6.9 hours of sleep on
weekdays (1). Sleep loss can occur through sleep deprivation or sleep restriction. Sleep
deprivation is the complete absence of sleep, while sleep restriction is interrupted sleep
cycles; these interruptions can occur through delayed sleep, intermittent waking, or early
awakening. The importance of sleep is believed to be related to a number of different
factors. A commonly accepted theory revolves around energy conservation, as sleep
reduces daily metabolic requirements and energy expenditure (15, 45). Also, despite early
data to the contrary, recent work clearly indicates that cognitive function is compromised
following sleep loss, suggesting the central nervous system is reliant on sleep for optimal
functioning (20, 59, 62).

Finally, there is compelling evidence that long-lasting

immunological memory is built through short adaptive immune responses that occur during
sleep (7). When adequate sleep is not achieved, the integrity of these systems is
compromised.
Athletes in particular require sufficient sleep, so as to facilitate recovery from the
physiological and psychological demands of heavy training and competition (3, 14, 35).
Sleep is believed to be critical for athletes due to restoration of the immune system,
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restoring the metabolic cost of the wakeful state, and enhancing memory, learning, and
synaptic plasticity (19, 25). Furthermore, when sleep is curtailed during periods of heavy
training, recovery is adversely affected and the potential for overtraining and maladaptation
arises, suggesting the necessity of sleep as a mode of recovery for athletes (4). When sleep
loss occurs acutely, restoration of neurocognition and the immune system is inhibited, and
could be a factor leading to decreased performance (25). Thus, sleep loss in athletes has
the potential to negatively affect the adaptive physiological and psychological recovery
processes. Moreover, athletes are especially susceptible to sleep loss. Many athletes
routinely perform consecutive days of high-intensity training bouts, and heavy training has
been shown to lead to impaired sleep (28). Further, the psychological stress of multi-day
competitions or target competitions can also lead to insufficient sleep. A survey examining
sleep habits of 632 athletes before an important competition or game reported that 62.3%
of them had experienced poor sleep in the nights before a sports event at least once in the
previous twelve months. Some athletes reported lost sleep had no effect on their athletic
performance, while others reported decrements in mood, alertness, and athletic
performance (17). When their schedules interfere with their sleep, whether involving late
bedtime or early arousal, the potential for short- and long-term consequences arises. The
deleterious effects of sleep on recovery and physical performance are therefore of interest
to both coaches and athletes.
Predictably, complete sleep deprivation has a negative impact on athletic
performance varying from strength and anaerobic exercise to prolonged aerobic exercise
(10, 38, 39, 43, 50, 52, 55). This could be at least partially related to the well documented
changes in perceived exertion and mood states following sleep deprivation (38, 43, 51, 52).
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Interestingly, the effects of sleep deprivation on physical performance are conflicting. With
the exception of one study, it would seem that sleep deprivation ranging from 30 to 60
hours decreases muscular strength and endurance (57). Significant decreases in muscular
strength and endurance were seen through decreased vertical jump, isokinetic knee
extension and flexion peak torque, and peak isometric voluntary force (10, 52, 58).
Conversely, data indicate that short-duration performances seem to be unaffected by sleep
deprivation (50, 55, 57, 58), with the exception of a recent report that 15-m sprint time was
significantly increased when subjects incurred 30 hours of sleep deprivation compared to
a full night of sleep (52). While the literature currently agrees that sleep deprivation can
substantially impair aerobic performance (3-20%), the mechanisms for these decrements
arise have yet to be explained. It would seem that cardiovascular, metabolic and ventilatory
changes occur as a result of sleep deprivation; however the effects of sleep on these
parameters are equivocal. In certain conditions, heart rate, oxygen consumption, and
ventilatory responses to exercise change with sleep deprivation, while in others these
measures stay the same. (38, 39, 43, 50, 57). Discrepancies in protocol may lead to the
conflicting evidence; especially in regards to hours of sleep deprivation and exercise
conditions. Studies have examined the effects of sleep deprivation in various amounts
exceeding 24 hours on performance outcomes which could include time to exhaustion, total
work, total distance covered, and maximal exercise intensity (5, 29, 37, 38, 42, 43). So, it
appears that sleep deprivation can lead to decreased athletic performance, most notably in
prolonged exercise.
In addition to sleep deprivation, some data has been gathered on the effects of acute
sleep restriction (i.e. a few hours of lost sleep) on performance. Sleep restriction seems to
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have equivocal effects on muscular strength. Reilly and Piercy reported that various
submaximal and maximal weight lifting tasks were negatively affected by sleep restriction,
while others report that handgrip and maximal voluntary contraction of muscles may either
decrease or remain unchanged, respectively (24, 48, 49, 54). The effect of sleep restriction
on anaerobic performance remains equivocal. While two studies have shown that there is
no change in anaerobic performance the morning following sleep restriction, a few have
reported decreased mean and peak power in a Wingate test the morning or evening
following sleep restriction (2, 24, 41, 55). Interestingly, all of the studies that demonstrated
performance decrements utilized early awakening as their form of sleep restriction (2, 24,
56). Similarly to total deprivation, the decrements seen in performance following sleep
restriction could be due to effects on RPE and mood states as opposed to physiological
mechanisms (24, 42, 56). Less is known about the effects of sleep restriction on aerobic
performances. While two studies showed sleep restriction did not affect incremental
running and cycling test durations the next day, others have demonstrated that sleep
restriction decreases performance in intermittent recovery and incremental cycling tests
(40, 42, 44, 48). Despite conflicting reports, it is clear that sleep restriction in the form of
early awakening is more disturbing to afternoon performance than delayed-bedtime
restriction for both aerobic and anaerobic exercise (2, 40, 56). It is important to consider
that the consequences of sleep restriction might vary due to individual differences such as
gender, age, morningness-eveningness classification (e.g. chronotype), amount of sleep
required, and sleep latency differences (9, 12, 26, 27). In light of the current literature, it
would seem that the effects of sleep restriction have negative consequences on
performance.
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Virtually everything that is known about sleep restriction and exercise performance
has been derived from subjects that refrained from heavy exercise leading up to the night
of sleep restriction. It is logical to expect that sleep loss following demanding exercise may
have a more pronounced effect on next-day exercise. In support of this idea, our laboratory
recently found that one night of sleep restriction following heavy exercise impairs shortduration cycling performance the following day by approximately 4 percent (13). Because
sleep disruption is inevitable and markedly detrimental to performance, it is worthwhile to
examine potential strategies to attenuate performance losses. One possible strategy to
minimize the effects of sleep restriction on performance is caffeine supplementation; as
caffeine would seem to have the potential to mitigate the detrimental effects of sleep
restriction through increased neurocognitive function and decreased perceived exertion (8).
Extensive research has demonstrated the effectiveness of caffeine as an ergogenic aid for
aerobic and anaerobic performance (22, 33, 34, 61). Additionally, our laboratory recently
reported that caffeine can enhance 3-km cycling time trial performance, especially early in
the day (8, 46). The extent to which caffeine may be able to compensate for the negative
effects of sleep loss has not been examined. Considering the efficacy of caffeine as a CNS
stimulant, it is plausible that caffeine could attenuate some of neurocognitive factors that
might lead to performance impairments (16). Therefore, the purpose of this investigation
is to test the hypothesis that caffeine supplementation will attenuate but not eliminate the
negative impact that sleep restriction has on next-day performance.
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Aims and Hypotheses
Aim 1: To determine if caffeine supplementation attenuates the negative effects of sleep
restriction on 3-km cycling TT performance.
Hypothesis 1: Caffeine supplementation will attenuate but not completely offset the
negative effects of sleep restriction on 3-km cycling TT performance.
Aim 2: To determine if caffeine supplementation attenuates the negative effects of sleep
restriction on muscle work during 30 isokinetic leg extension repetitions.
Hypothesis 2: Caffeine supplementation will attenuate but not completely offset the
negative effects of sleep restriction on muscle work during 30 isokinetic leg extension
repetitions.
Aim 3: To determine if caffeine supplementation attenuates the negative effects of sleep
restriction on mood states.
Hypothesis 3: Caffeine supplementation will attenuate but not completely offset the
negative effects of sleep restriction on mood states.
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Significance
Sleep plays an important role in psychological and physiological recovery from
exercise. Despite a resounding belief from athletes and coaches that sleep is critical to
recovery and performance, the role sleep plays in enhancing recovery and promoting
performance is still ambiguous. Little has been done to determine the effects of sleep
restriction on recovery from heavy exercise and subsequent performance. Sleep restriction
appears to negatively affect performance in athletes, especially when sleep restriction
occurs in the form of early awakening. This seems to be due to negative impacts on
cognitive functioning and mood states, however there may be underlying physiological
mechanisms as well. Furthermore, potential strategies to mitigate performance decrements
observed following sleep restriction have yet to be tested. Considering the prevalence of
sleep loss in athletic populations, it is important to investigate the effects sleep restriction
has on recovery from exercise as well as potential ways to ameliorate resulting decrements.
The current study has the potential to determine if caffeine supplementation can serve as a
method to improve 3km cycling time trial performance following heavy exercise and sleep
restriction.
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Chapter Two
Methods
Subjects
Eight to fifteen male and female recreational cyclists from James Madison
University will participate in this study. All subjects must perform a minimum of 30
minutes of cycling, one to two days per week, for at least three months prior to the study,
and possess a maximum oxygen consumption (VO2max) of ≥ 40 ml/min/kg to qualify for
participation. Additionally, participants will score ≤ 7 on the Pittsburg Sleep Quality Index
(PSQI) to ensure they have “normal” sleeping habits (11). Participants will be informed of
the experimental protocol, risks, and benefits before providing written consent. The study
will has been approved by the James Madison Institutional Review Board.

Preliminary Testing
Following height and weight measurements, participants will perform an
incremental exercise test to exhaustion on a cycle ergometer (Velotron, Racermate, Inc.,
Seattle, WA, USA) to determine VO2max and maximum power in watts (Wmax). The
participants will warm up for five minutes at a self-selected workload, then begin the test
at a workload between 100 and 175 W. The workload will increase every 2 minutes in 50
W increments until volitional fatigue or inability to maintain a cadence of 50 RPM or
higher for more than 10 seconds. Expired air will be collected throughout the test and
oxygen consumption (VO2) will be assessed using the Moxus Modular Metabolic System
(AEI Technologies, Pittsburgh, PA, USA). VO2max will be determined by the highest 30-s
mean VO2.
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Experimental Design
Participants will complete a familiarization phase followed by four experimental
phases, each separated by five to seven days. The familiarization and experimental phases
will consist of two exercise sessions performed on consecutive days (EX1 and EX2). EX1
will consist of baseline performance testing followed by an exercise protocol designed to
elicit fatigue. EX2 will be performed the following morning to assess recovery from the
exercise protocol, and will only include the performance testing. EX1 and EX2 during the
experimental phases will be separated by a night of full sleep (FULL) or a night of restricted
sleep (SR). Sleep will be assigned to each participant in a randomized, crossover design.
Participants will be informed of their designated sleep condition following the exercise
protocol on EX1 and not before, to prevent reactive behavior changes leading up to the
experimental trials.

Familiarization Phase
The familiarization phase will consist of EX1 and EX2 trials (as described below)
without controls for sleep, diet, and physical activity. The participants will complete the
trials at predetermined intensities to confirm they can complete the protocol, familiarize
themselves with the equipment, and reduce learning-related improvements in performance
during the experimental trials.

Experimental Trial 1 (EX1)
Participants will arrive at the Human Performance Lab between 3:00 and 5:00pm,
having abstained from alcohol, tobacco, or caffeine for 24 hours. Additionally, they will
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arrive fasted for ≥2 hours. Upon arrival, participants will be equipped with a heart rate
(HR) monitor (Polar; Lake Success, NY, USA) to wear, and then rest in a reclined position
for five minutes. At the cessation of the five minute period, resting HR will be recorded.
Participants will then warm up for 20 minutes (10 minutes at 50% Wmax followed by 10
minutes at 60% Wmax) on the aforementioned cycle ergometer, during which metabolic
measurements will be assessed, as described below. Following the 20 minute warm-up,
participants will begin a computer simulated 3-km cycling time trial. Participants will be
encouraged to give a maximal effort before the time trial. Following the time trial,
participants will cool down on the bicycle ergometer at a self-selected intensity between
50-100W for 10 minutes. The cool-down intensity will be matched in subsequent trials.
Following the cool-down, participants will perform three warm-up and 30 maximal singleleg extensions at 120°/second on an isokinetic dynamometer (Biodex Multi-Joint System PRO, Biodex Medical Systems, Inc., Shirley, NY, USA). Upon completion of leg
extensions, participants will perform a 60-minute sprint interval session, previously used
in our laboratory (13). Intervals will alternate between 2 minutes at 95% Wmax and 2
minutes at 50% Wmax. If participants cannot maintain a cadence of ≥50 rpm at 95%
Wmax, power output will be reduced by 10% for following sprints.

Experimental Trial 2 (EX2)

Participants will begin EX2 between 7:00am and 9:00am the following morning.
Participants will eat a standardized breakfast (detailed below) 2 hours prior to EX2.
Caffeine/placebo capsules will be ingested 1 hour prior to EX2. Resting HR will be
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recorded after 5 minutes of rest at the start of EX2. Following rest, participants will
complete an assessment of transient mood states (POMS-2, Multi-Health System; North
Tonawanda, NY, USA). Participants will then repeat the warm up and time trial protocol
from EX1 and cool down on the cycle ergometer at their previously selected intensity.
Following the cool-down, participants will perform the same leg-extension protocol from
EX1.

Sleep Protocol
Participants will undergo the four experimental trials with 5-7 days between the
end of one trial and beginning of another. Participants will be instructed to initiate sleep
between 10:00 pm and 12:00 am for all FULL and SR trials, replicating the same onset
time in all experimental phases. For FULL, participants will be instructed to set their wakeup time for 8 hours following sleep onset. After waking up, participants will report to the
laboratory for EX2. For SR, participants will be instructed to set their wake-up time 3.5
hours following sleep onset. After waking up, participants will immediately report to the
laboratory whereupon an investigator will accompany them to ensure wakefulness until
testing begins. The start time of EX2 will remain constant throughout the experimental
phases. The Sleep Cycle smartphone application (Northcube, AB, Göteborg, Sweden) will
be used to evaluate the two nights preceding EX1 and the night before EX2. Participants
will place the smart phone on their mattress in accordance with manufacturer
recommendations and sleep data will be estimated based on motion detection. In addition
to Sleep Cycle, sleep data will be acquired through the use of an Actigraph Accelerometer
(Pensacola, FL, USA) worn on the non-dominant wrist.
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Caffeine/Placebo Capsules:
A randomly counterbalanced, double blind, placebo controlled design will be
utilized to compare the effects of four different treatment conditions. Participants will
receive 6mg/kg body weight in capsule form containing either rice flour (PLA) or
anhydrous caffeine. Capsules will be ingested 1 hour before each EX2 trial. The four
treatment conditions will be: FULL with caffeine capsule (FULL/CAF), 2. FULL with
placebo capsule (FULL/PLA), 3. SR with caffeine capsule (SR/CAF), and 4. SR with
placebo capsule (SR/PLA).

Dependent Measures
3-km Time Trial Performance
3-km time trial performances will be performed on the Velotron cycle ergometer in
all EX trials. Time to completion and average power output will be used as the primary
performance measures.

Blood Lactate and Glucose
Blood lactate and glucose will be taken at minute 18 of the 20 minute warm-up
preceding the 3-km time trial in all EX trials. A finger-stick blood draw will be performed
and blood will be analyzed in a YSI 2300 Stat Plus Analyzer (YSI Incorporated; Yellow
Springs, OH, USA).
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Muscle Function
Total work and fatigue index will be determined using the Biodex dynamometer
mentioned above at 120°/second during all EX trials.

Oxygen Consumption, Ventilation, & Respiratory Exchange Ratio (VO2, VE, & RER)
VO2, VE, and RER will be measured using a Moxus metabolic cart during the last
5 minutes of the 20 minute warm-up preceding the 3-km time trial in all EX trials. Values
obtained in minutes 17-20 will be averaged and recorded.

Heart Rate & Rate of Perceived Exertion (HR & RPE)
During all EX trials, HR and RPE will be obtained at minute 20 of the 20 minute
warm-up preceding the 3-km time trial.

Dietary and Exercise Controls
Participants will record all food and beverage intake for 24 hours before EX1 and
continue recording until sleep onset that night. After the first EX phase, copies of food and
beverage logs will be provided to the participants to replicate diet habits for the remaining
phases. Participants will begin all EX trials after a ≥2 hour fast. Within one hour of
completing EX1, participants will consume a meal replacement protein shake (Ensure
Original Nutrition Shake, Abbott Laboratories). Participants will also be asked to abstain
from consuming any other macronutrients within two hours of ending EX1. For all
conditions, participants will be instructed to consume a standardized breakfast 2 hours
before beginning EX2. The standardized breakfast will consist of orange juice, cereal, and
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yogurt equaling approximately 400 calories. Participants will also be instructed to record
all physical activity for 72 hours prior to EX1 in all phases, and keep physical activity
habits for all phases. Additionally, they will be instructed to avoid physical activity the day
of EX1 and between EX1 and EX2.

Statistics
Total time to completion and mean power output (Watts) during the 3-km time trial
will be used as the performance measures. Data will be log transformed to reduce the
effects of non-uniformity. Magnitude-based inferences will be derived about the data using
methods previously described by Hopkins and colleagues (32). A previously determined
“smallest worthwhile change” in performance will be used as a threshold value for a
condition effect (EX1 time trial vs. EX2 time trial). The smallest worthwhile change in
performance is defined as 0.3 x the within subject variability of select groups of elite
cyclists across repeated time trials (CV = 1.5% for time and estimated 4.5% for power)
(31). For all other variables that will be analyzed, the threshold value for a substantial
treatment effect will be defined as 0.2 x within-subject standard deviation, under resting
conditions.
Publically available spreadsheets will be used to the likelihood of the true treatment
effect (of the population) reaching the substantial change threshold (30). The percent
likelihoods will be classified as: <1% almost certainly no chance, 1-5% = very unlikely, 525% = unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, >99% almost
certain. Clinical inference criteria will be used to classify the effects of all conditions on
performance. If the percent chance of the effect reaching the substantial change threshold
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is <25% and the effect is clear, it will be classified as ‘trivial’. If the percent chance of the
effect reaching the substantial change threshold for benefit exceeds 25%, but the chance
for harm is >0.5%, the effect will be considered “unclear”. An exception to the 0.5% chance
of harm criterion will be made if the benefit/harm odds ratio is >66, in which the case of
the effect will be interpreted as “clear”.
Following individual condition analysis, treatment comparisons (FULL/CAF vs
FULL/PLA vs SR/CAF vs SR/PLA) outcomes will be assessed using the previously
mentioned spreadsheets (30). The classification system described above will apply, but
mechanistic criteria will be used. If 90% confidence intervals include values that exceed
the substantial change threshold for both a positive and negative effect, the effect will be
considered ‘unclear’.
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Chapter 3
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Abstract
Introduction: Although a full understanding of the role of sleep is debated, it is
widely accepted that sleep is important for recovery from heavy exercise. Recent research
suggests that sleep restriction (SR) may negatively impact recovery and subsequent
performance. It is unknown if caffeine supplementation mitigates this performance
decrement. Our objective was to investigate the effect of caffeine supplementation on
exercise performance following one night of SR in trained cyclists.
Methods: Subjects (n=10) completed a 3-km time trial (TT) and an exhaustive bout
of exercise in the evening (EX1), then returned to repeat the TT the following morning
(EX2). Exercise trials were separated by a full night of sleep (FULL) or a night of restricted
sleep (SR). Perceived fatigue was also assessed prior to EX2. Caffeine (CAF) or placebo
(PLA) treatments were given before the start of EX2. A randomly counterbalanced, double
blind, placebo controlled design was used to compare the effects of four different treatment
conditions: FULL/PLA, SR/PLA, FULL/CAF, and SR/CAF.
Results: Data were analyzed using magnitude-based inferences to compare
differences in EX2 performances only. Power output was ‘possibly’ greater (0.9 ± 3.6%)
following SR/PLA compared to FULL/PLA. Power output was ‘likely’ higher (5.5 ± 4.8%)
following SR/CAF compared with SR/PLA. Perceived fatigue was rank ordered as 1)
SR/PLA, 2) SR/CAF, 3) FULL/PLA, 4) FULL/CAF. Specifically, CAF ‘very likely’
reduced perceived fatigue following SR compared to SR PLA, but remained ‘likely’ higher
than FULL/CAF.
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Conclusion: These data show that caffeine has the ability to mitigate performance
decrements resulting from a single night of SR following heavy exercise. Caffeine also
prevented increases in perceived fatigue following SR.
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Introduction

A full understanding of the precise physiological role of sleep has yet to be fully
elucidated, but it is clear that sleep is required for optimal function. It is widely
recommended that adults sleep 7 to 9 hours a night. Despite this recommendation, much
of the population falls short of these guidelines (18, 60). The importance of sleep is
believed to be related to energy conservation and optimal central nervous and immune
system function (7, 15, 20, 45, 59, 62). Proper sleep may be critical to recovery for
athletes due to maintenance of the immune system, restoring the metabolic cost of the
wakeful state, preventing overtraining, and enhancing memory, learning, and synaptic
plasticity (4, 19, 25). In addition, athletes are particularly susceptible to sleep loss due to
heavy training and psychological stress of competitions (17, 28). Therefore, it is
advantageous for both coaches and athletes to understand the effects of sleep on recovery
and physical performance.
Complete sleep deprivation (SDEP; i.e. >24 hrs sleep loss) reportedly has
negative impacts on athletic endeavors, ranging in duration from short sprints and
Wingate tests (90s) to endurance trials lasting approximately 35 to 100 minutes.
However, there is still some debate regarding the mechanisms which underlie these
performance decrements (38, 43, 52, 55, 57). The detrimental effects of SDEP on
performance have been at least partially attributed to changes in perceived exertion and
mood states following SDEP, but the direct mechanisms have yet to be fully determined
(38, 43, 51, 52). Although athletes may occasionally experience SDEP, it is presumably
more common for athletes to experience acute sleep restriction (SR; abbreviated sleep
duration) as a result of late bedtime, intermittent awakening, or early awakening. It would

21

seem that SR can negatively impact peak and mean muscular power, especially when
performance is in the afternoon (2, 24, 41, 55). The effects of SR on longer performances
such as cycling and running time to exhaustion as well as shuttle running are
unequivocal. Early research indicated that SR had no effect on these performances.
However, more recent data suggest that SR in the form of early awakening as opposed to
delayed bedtime can inhibit performance in the afternoon suggesting the type of SR as
well as the time of performance are key factors when investigating the implications of SR
(40, 42, 44, 48).
Prior studies on SR and exercise performance had subjects refrain from heavy
exercise leading up to the night of SR. Our laboratory recently found that one night of SR
following heavy exercise impairs short-duration cycling performance by approximately
4% (13). Because SR is inevitable and in some cases, detrimental to performance, it is
worthwhile to examine potential strategies to attenuate performance detriments following
SR. One potential strategy is caffeine supplementation. Extensive research has
demonstrated the effectiveness of caffeine as an ergogenic aid for performance through
increased neurocognitive function and decreased perceived exertion (22, 33, 34, 61).
Specifically, Souissi et al recently investigated the effects of caffeine on physical and
cognitive performance following 36 hours of SDEP. Caffeine ingestion following SDEP
improved mood states, cognitive function, squat jump and Wingate performance (53).
While this data presents a strong case for caffeine mitigating the performance losses seen
following SDEP, it is important to note that the tests were performed in the afternoon,
sleep loss occurred through total SDEP, and subjects were fully rested leading into the
study. Thus, it is important to investigate the role of caffeine in attenuating the
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detrimental performance following sleep restriction. Therefore, the purpose of the present
investigation is to test the hypothesis that caffeine supplementation will attenuate but not
fully compensate for the negative impact that SR has on next-day performance.
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Methods
Subjects
Ten male (n=8) and female (n=2) recreational cyclists from James Madison
University participated in this study. All subjects performed a minimum of 30 minutes of
cycling, one to two days per week, for at least three months prior to the study, and possessed
a maximum oxygen consumption (VO2max) of ≥ 40 ml/min/kg. Demographic information
of the participants is highlighted in Table 1. Additionally, participants scored ≤ 7 on the
Pittsburg Sleep Quality Index (PSQI) to ensure they had “normal” sleeping habits (11).
Participants were informed of the experimental protocol, risks, and benefits before
providing written consent. The study was approved by the James Madison Institutional
Review Board
Preliminary Testing
Following height and weight measurements, participants performed an incremental
exercise test to exhaustion on a cycle ergometer (Velotron, Racermate, Inc., Seattle, WA,
USA) to determine VO2max and maximum power in watts (Wmax). The participants
warmed up for five minutes at a self-selected workload, then began the test at a workload
between 100 and 175 W based on self-reported training workloads. The workload increased
every 2 minutes in 50 W increments until volitional fatigue or inability to maintain a
cadence of 50 RPM or higher for more than 10 seconds. Breath samples were collected
throughout the test and oxygen consumption was assessed using the Moxus Modular
Metabolic System (AEI Technologies, Pittsburgh, PA, USA). VO2max was be determined
by the highest 30-s mean oxygen uptake value.

24

Experimental Design
Participants completed a familiarization phase followed by four experimental
phases, each separated by five to seven days. The familiarization and experimental phases
consisted of two exercise sessions performed on consecutive days (EX1 and EX2). EX1
consisted of baseline performance testing followed by an exercise protocol designed to
elicit fatigue. EX2 was performed the following morning to assess recovery from the
exercise protocol, and only included the performance testing. EX1 and EX2 during the
experimental phases were separated by a night of full sleep (FULL) or a night of restricted
sleep (SR). Sleep condition was assigned to each participant in a randomized, crossover
design. Participants were informed of their designated sleep condition following the
exercise protocol on EX1 and not before, to prevent reactive behavior changes leading up
to the experimental trials. A schematic of the experimental design can be found in Figure
1.
Familiarization Phase
The familiarization phase consisted of EX1 and EX2 trials (as described below),
however sleep, diet, and physical activity were not controlled. These trials were performed
at predetermined intensities calculated from Wmax to confirm they could complete the
protocol, familiarize themselves with the equipment, and reduce learning-related
improvements in performance during the experimental trials. Appropriate intensities for
the various components of the experimental trials are defined below.
Experimental Trial 1 (EX1)
Participants arrived at the Human Performance Lab between 3:00 and 5:00pm,
having not consumed alcohol, tobacco, or caffeine for 24 hours. Additionally, they arrived
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having fasted from food for ≥2 hours. Upon arrival, participants were equipped with a heart
rate (HR) monitor (Polar; Lake Success, NY, USA) to wear, and then rested in a reclined
position for five minutes. At the cessation of the five minute period, resting HR was
recorded and weight was measured. Participants warmed up for 20 minutes (10 minutes at
50% Wmax followed by 10 minutes at 60% Wmax) on the aforementioned cycle
ergometer, during which metabolic measurements were assessed, as described below.
Following the 20 minute warm-up, participants began a computer simulated 3-km cycling
time trial. Participants were encouraged to give a maximal effort before the time trial.
Following the time trial, participants cooled down on the bicycle ergometer at a selfselected intensity between 50-100W for 10 minutes. The cool-down intensity was matched
in subsequent trials. Following the cool-down, participants performed three warm-up and
30 maximal single-leg extensions at 120°/second on an isokinetic dynamometer (Biodex
Multi-Joint System - PRO, Biodex Medical Systems, Inc., Shirley, NY, USA). Upon
completion of leg extensions, participants performed a 60-minute sprint interval session,
previously used in our laboratory (13). Intervals alternated between 2 minutes at 95%
Wmax and 2 minutes at 50% Wmax. If participants could not maintain a cadence of ≥50
rpm at 95% Wmax, power output was reduced by 10% for following sprints. Upon leaving
the laboratory, participants were instructed to continue refraining from the consumption of
alcohol, tobacco, or caffeine.
Experimental Trial 2 (EX2)
Participants began EX2 between 7:00am and 9:00am the following morning.
Participants ate a standardized breakfast (detailed below) 2 hours prior to EX2.
Caffeine/placebo capsules were ingested 1 hour prior to EX2. Resting HR was recorded
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after 5 minutes of rest at the start of EX2. Following rest, participants completed an
assessment of transient mood states (POMS-2, Multi-Health System; North Tonawanda,
NY, USA). Participants then repeated the warm up and time trial protocol from EX1.
Participants cooled down on the cycle ergometer at their previously selected intensity.
Following the cool-down, participants performed the same leg-extension protocol from
EX1.
Sleep Protocol
Participants were instructed to initiate sleep between 10:00 pm and 12:00 am for
all FULL and SR trials, and replicated the same onset time in all experimental phases. For
FULL, participants were instructed to set their wake-up time for 8 hours following sleep
onset. After waking up, participants reported to the laboratory for EX2. For SR, participants
were instructed to set their wake-up time 3.5 hours following sleep onset. After waking up,
participants immediately reported to the laboratory whereupon an investigator
accompanied them to ensure wakefulness until testing began. The start time of EX2
remained constant throughout the experimental phases. The Sleep Cycle smartphone
application (Northcube, AB, Göteborg, Sweden) was used as to confirm adherence for the
two nights preceding EX1 and the night before EX2. Participants placed the smart phone
on their mattress in accordance with manufacturer recommendations and sleep data was
estimated based on motion detection. In addition to Sleep Cycle, sleep data was acquired
through the use of an accelerometer (ActiGraph GT3X+, ActiGraph Corp, Pensacola, FL,
USA) worn on the non-dominant wrist. Sleep amounts acquired by participants can be
found in Table 2.
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Caffeine/Placebo Capsules:
A randomly counterbalanced, double blind, placebo controlled design was utilized
to compare the effects of four different treatment conditions. No treatments were
administered during the familiarization trials. During the experimental trials participants
were given 6mg/kg body weight in capsule form containing either rice flour (PLA) or
anhydrous caffeine (CAF). Capsules were ingested 1 hour before each EX2 trial. The four
treatment conditions were: FULL with caffeine capsule (FULL/CAF), 2. FULL with
placebo capsule (FULL/PLA), 3. SR with caffeine capsule (SR/CAF), and 4. SR with
placebo capsule (SR/PLA).
Dependent Measures
3-km Time Trial Performance
3-km time trial performances were performed on the Velotron cycle ergometer in
all EX trials. Time to completion and average power output were used as the primary
performance measures.
Responses to Fixed-Load Exercise
Oxygen Consumption, Ventilation, & Respiratory Exchange Ratio (VO2, VE, and
RER)
VO2, VE, and RER were measured using a Moxus metabolic cart during the last 5
minutes of the 20 minute fixed-load phase preceding the 3-km time trial in all
experimental trials. Values obtained in minutes 17-20 were averaged and recorded.
Heart Rate & Rate of Perceived Exertion (HR & RPE)
During all experimental trials, HR and RPE were obtained at minute 20 of the 20
minute fixed-load phase preceding the 3-km time trial.
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Muscle Function
Total work, peak torque, and fatigue index over 30 maximal leg extensions were
determined using the Biodex dynamometer mentioned above at 120°/second during all EX
trials. Total work was the sum of work done in Joules (J) over the course of the 30 maximal
leg extensions. Fatigue index was calculated for the 30 maximal leg extensions as a percent
change using the formula
[

𝑃𝑒𝑎𝑘 𝑇𝑜𝑟𝑞𝑢𝑒 5 𝑠𝑡𝑟𝑜𝑛𝑔𝑒𝑠𝑡 𝑟𝑒𝑝𝑖𝑡𝑖𝑡𝑖𝑜𝑛𝑠 − 𝑃𝑒𝑎𝑘 𝑇𝑜𝑟𝑞𝑢𝑒 5 𝑤𝑒𝑎𝑘𝑒𝑠𝑡 𝑟𝑒𝑝𝑒𝑡𝑖𝑡𝑖𝑜𝑛𝑠
] × 100
𝑃𝑒𝑎𝑘 𝑇𝑜𝑟𝑞𝑢𝑒 5 𝑠𝑡𝑟𝑜𝑛𝑔𝑒𝑠𝑡 𝑟𝑒𝑝𝑖𝑡𝑖𝑡𝑖𝑜𝑛𝑠

Dietary and Exercise Controls
Participants recorded all food and beverage intake for 24 hours before EX1 and
continued recording until sleep onset that night. After the first EX phase, copies of food
and beverage logs were provided to the participants to replicate diet habits for the
remaining phases. Participants began all EX trials after a ≥2 hour fast. Within one hour of
completing EX1, participants consumed a meal replacement protein shake. Participants
were asked to abstain from consuming any other macronutrients within two hours of ending
EX1. For all conditions, participants were instructed to consume a standardized breakfast
2 hours before beginning EX2. The standardized breakfast consisted of orange juice, cereal,
and yogurt equaling approximately 400 calories. Participants were also instructed to record
all physical activity for 72 hours prior to EX1 in all phases, and keep physical activity
habits for all phases. Additionally, they were instructed to avoid physical activity the day
of EX1 and between EX1 and EX2.

Statistics
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Total time to completion (min) and mean power output (Watts) were used as the
main performance measures, while isokinetic testing was used to assess muscle function.
Data was log transformed to reduce the effects of non-uniformity. Magnitude-based
inferences were derived about the data using methods previously described by Hopkins
and colleagues (32). A previously determined “smallest worthwhile change” in
performance was used as a threshold value for a between condition effect (EX2 time trial
vs. EX2 time trial). The smallest worthwhile change in performance was defined as 0.3 x
the within subject variability of select groups of elite cyclists across repeated time trials
(CV = 1.5% for time and estimated 4.5% for power) (31). For all other variables that were
analyzed, the threshold value for a substantial treatment effect was defined as 0.2 x withinsubject standard deviation, under resting conditions.
Publically available spreadsheets were used to the likelihood of the true treatment
effect (of the population) reaching the substantial change threshold (30). The percent
likelihoods were classified as: <1% almost certainly no chance, 1-5% = very unlikely, 525% = unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, >99% almost
certain. Clinical inference criteria were used to classify the effects of all conditions on
performance. If the percent chance of the effect reaching the substantial change threshold
was <25% and the effect is clear, it was classified as ‘trivial’. If the percent chance of the
effect reaching the substantial change threshold for benefit exceeded 25%, but the chance
for harm was >0.5%, the effect was considered “unclear”. An exception to the 0.5% chance
of harm criterion was made if the benefit/harm odds ratio was >66, in which the case of the
effect was interpreted as “clear”.

30

Following individual condition analysis, treatment comparisons (FULL/CAF vs
FULL/PLA vs SR/CAF vs SR/PLA) outcomes were assessed using the previously
mentioned spreadsheets (30). The classification system described above was applied, but
mechanistic criteria was used. If 90% confidence intervals included values that exceeded
the substantial change threshold for both a positive and negative effect, the effect was
considered ‘unclear’. All data are presented as means ± SD.
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Results
3-km Time Trial Performance
Statistics were performed on 3-km TT power output and mean values displayed in
Figure 2. For reference, EX2 finishing times were as follows: FULL/PLA, 301.1 ± 32.2
sec; SR/PLA, 300.7 ± 33.2 sec; FULL/CAF, 296.9 ± 37.8 sec; SR/CAF, 294.8 ± 39 sec.
Statistics were performed on EX2 power output, but for reference, finishing times were as
follows: Time trial performance had a clear order effect such that they rode progressively
slower chronologically. Therefore, EX1 3-km TT performances were aggregated and are
only used as a reference point in comparison to EX2 performances in the four experimental
conditions. Average time trial power output for EX1 was 273.7 ± 69.2 W (mean finishing
time: 294.9 ± 32.8 sec). For all conditions except SR/CAF, average power output and
finishing time were lower the following morning for EX2. All comparisons presented
henceforth are from the EX2 (morning) trials. Power output was ‘possibly’ greater (0.9 ±
3.6%) following SR/PLA compared to FULL/PLA. Power output was ‘likely’ higher (5.5
± 4.8%) following SR/CAF compared with SR/PLA. There were ‘unclear’ (1.9 ± 3.2%)
differences in power output following SR/CAF compared to FULL/CAF. Power output
was ‘very likely’ greater (6.5 ± 5.2%) following SR/CAF compared to FULL/PLA.
Muscle Function
Peak isokinetic torque, total work, and fatigue index data at 120 deg∙sec-1 are
displayed in Table 3. There were no differences in peak torque between any of the
experimental conditions.
Total Work
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There was a ‘likely trivial’ difference in total work (˗2.0 ± 6.4%) between SR/PLA
and FULL/PLA. However, total work was ‘possibly’ higher (4.9 ± 7%) following SR/CAF
compared to SR/PLA. Finally, there was a ‘likely trivial’ difference (3.5 ± 3.6%) between
FULL/CAF and SR/CAF.
Fatigue Index
There were no differences in fatigue index when comparing FULL/PLA to
SR/CAF, SR/PLA to SR/CAF, and FULL/CAF to SR/CAF. However, fatigue index was
‘very likely’ higher (18.1 ± 11.5%) following FULL/PLA compared to SR/PLA.
Muscle Soreness
Sleep condition did not seem to affect muscle soreness in the placebo or caffeine
treatments. Additionally, treatment did not seem to affect muscles soreness following a
night of sleep restriction. Muscle soreness was only different when comparing SR/CAF to
FULL/PLA. Surprisingly, muscle soreness was ‘most likely’ lower (-42.7 ± 14.4%)
following SR/CAF (20.8 ± 10.9mm) compared to FULL/PLA (34.7 ± 15mm).
Responses to Fixed-Load Exercise
HR and RPE
There were no differences in fixed-load HR between FULL/PLA and SR/PLA or
between SR/CAF and SR/PLA. Fixed-load HR was ‘possibly’ higher (2.4 ± 3.4%)
following SR/CAF compared to FULL/CAF.
There was no difference in RPE when comparing SR/PLA to FULL/PLA. RPE was
‘very likely’ lower (-9.5 ± 4.4%) following SR/CAF compared to SR/PLA. Additionally,
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RPE was ‘very likely’ lower following SR/CAF compared to FULL/PLA. Sleep condition
had a ‘very likely’ effect on RPE with the caffeine treatment. Interestingly, RPE was ‘very
likely’ lower (-7.4 ± 4.8%) following SR/CAF compared to FULL/CAF.
VO2, VE, and RER
Sleep condition had an ‘unclear’ effect on VO2 during the placebo treatment (1.4 ±
4.9%). VO2 was ‘likely’ lower (-5.3 ± 5.2%) following FULL/PLA compared to SR/CAF.
There was a ‘possible’ effect of treatment (3.8 ± 6%) on morning performance. VO2 was
‘possibly’ lower for SR/PLA compared to SR/CAF. Similarly, VO2 was ‘possibly’ lower
(-2.0 ± 3.4%) following FULL/CAF compared to SR/CAF.
There were ‘unclear’ (0.3 ± 4.2%) differences between SR/PLA and FULL/PLA.
Ventilation was ‘likely’ elevated (5.7 ± 5.2%) following SR/CAF compared to SR/PLA.
Also, ventilation was ‘possibly’ elevated (1.5 ± 3.3%) SR/CAF (77 ± 8.9 L/min) compared
to FULL/CAF.
There were ‘unclear’ differences in RER for all comparisons except when
comparing FULL/PLA to SR/CAF (1.1 ± 1.6%). RER was ‘possibly’ lower for the
FULL/PLA than for SR/CAF.
Profile of Mood States
Total Mood Disturbance
Data for POMS total mood disturbance are displayed in Table 3. Total mood
disturbance was ‘likely’ higher (7.1 ± 5.5%) following SR/PLA compared to FULL/PLA.
Total mood disturbance was ‘possibly’ lower (-2.0 ± 3.8%) following SR/CAF compared
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to SR/PLA and ‘very likely’ lower (-7.5 ± 3.9%) following FULL/CAF as compared to
SR/CAF.
Fatigue-Inertia
Fatigue-inertia was ‘very likely’ (11 ± 7.4%; 92% likelihood) greater following
SR/PLA compared to FULL/PLA. Fatigue-inertia was ‘very likely’ greater (8.3 ± 5.5%)
following SR/PLA compared to SR/CAF. Additionally, fatigue-inertia was ‘likely’ greater
(6.2 ± 8%) following SR/CAF compared to FULL/CAF.
Vigor-Activity
Vigor-activity was ‘possibly’ lower (-7.3 ± 7.6%) in SR/PLA compared to
FULL/PLA. Conversely, vigor-activity was ‘likely’ greater (18.3 ± 16.8%) following
SR/CAF (47.4 ± 10.2) compared to SR/PLA. Additionally, vigor-activity was ‘possibly’
lower (-4.2 ± 7.9%) following SR/CAF compared to FULL/CAF.
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Discussion
This study was designed to investigate the effect of sleep restriction on next
morning cycling time trial performance following heavy exercise. Specifically, the goal of
this study was to explore whether caffeine can compensate for the performance decrements
following sleep restriction recently reported by our laboratory (13). Interestingly, there
were no differences in performance between FULL/PLA compared to SR/PLA as
previously suggested, but these findings may have been confounded by a nocebo effect
(13, 47). Regardless, the most notable finding was that participants had ‘very likely’
increased power output (6.5%) following SR/CAF compared to FULL/PLA. While we
anticipated that caffeine would attenuate performance decrements following sleep
restriction, we did not expect to see performance exceeding that of a full night of sleep
under any of the sleep restriction conditions. Although greater than expected, there was a
‘likely’ improvement in power output (5.5%) following SR/CAF compared to SR/PLA.
No systematic differences in muscle function were observed. This is consistent with our
recent report that even with impaired recovery (as evidenced by 3-km time trial
performance), there were no differences in muscle function (13). The majority of
cardiorespiratory variables taken during the fixed-load phase prior to the time trial in the
SR/CAF condition were altered. Specifically, ventilation, VO2, and HR were ‘possibly’
and ‘likely’ elevated. Altogether, these data suggest that caffeine supplementation can
benefit performance through increasing power output following both sleep restriction and
a full night of sleep.
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The effects of sleep restriction on recovery from exercise have been investigated in
only a few studies. One observational study reported decreased sleep duration negatively
impacted perceived recovery the following morning in elite soccer players that participated
in night matches compared to day matches. While there were no specific performance
measures, players reported lower perceived recovery following night matches and
decreased sleep duration (21). Additional quantitative research supports the notion that
sleep facilitates recovery. Previous findings showed a 4-5% decrease in cycling
performance following heavy exercise and sleep restriction, presumably due to diminished
muscle glycogen replenishment as well as reduced restoration of the immune and endocrine
systems (13, 16, 47, 52). Despite such findings, the current study did not observe any
difference in performance following heavy exercise and sleep restriction compared to a full
night of sleep. Even with a full night of sleep it appears that the participants in this study
had a difficult time recovering from the heavy exercise, whereas in our previous research
and the study by Rae et al, the participants seemed to sufficiently recovery from previous
exercise with a full night of sleep. What makes this finding even more surprising is that the
negative psychological effects (mood disturbance, sleepiness, fatigue, etc.) of sleep
restriction (49, 51), which have been used to explain impaired next-day performance, were
present with SR compared to FULL. If the psychological alterations do contribute to
performance impairment, they were not marked enough to influence performance in the
current study. Due to the multifaceted nature of recovery, it is difficult to identify the reason
for the inconsistent performance findings. One possible explanation for the current
outcome is the nocebo effect, or worsening performance due to the expectation of negative
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outcome (6). While our study was not designed to test the nocebo effect, it may be that
subjects underperformed when they were confident that they were not receiving the
caffeine treatment, as has been shown in previous literature. Six of our ten subjects were
able to accurately identify when they received the placebo in the present study, which could
be a reason they underperformed following placebo treatments. Furthermore, the
participants in the current study certainly experienced the negative psychological effects
of sleep restriction. It is well known that disrupted sleep causes disturbances in mood (49,
51). Total mood disturbance following sleep restriction was 7.1% greater than a full night
of sleep in the placebo condition. Furthermore, an 11% increase in fatigue was observed in
the sleep restriction condition compared to the full night of sleep under placebo treatment.
Despite the greater mood disturbance following sleep restriction, it was not enough to
impact performance compared to FULL/CAF.
While the results in the FULL/PLA condition were surprising, the outcomes
following caffeine supplementation were more consistent with our hypothesis. Following
sleep restriction, when participants received caffeine treatment, they had 5.5% greater
power output than when they received placebo. This was enough of an increase to maintain
3-km TT performance from the previous evening. This increase in power output with
caffeine following SR supports the well-established efficacy of caffeine as an ergogenic
aid for short-duration cycling performance (22, 33, 34, 61) as well as Wingate performance
following sleep deprivation (53). Previous research by Souissi et al. demonstrated that
when Wingate performance was assessed 36 hours following SDEP, caffeine improved
peak and mean power output compared to placebo. Additionally, when compared to the
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placebo treatment following sleep restriction, caffeine supplementation resulted in similar
peak and mean power output compared to a full night of sleep without caffeine (53). Along
with altering performance, caffeine also moderately influenced psychological measures.
After ingesting caffeine, participants had a modest but ‘possible’ 2% reduction in total
mood disturbance in the sleep restriction condition compared to placebo. Although smaller
in magnitude, these findings are in line with the literature, which documents decreased
mood following sleep restriction, and furthermore, improved mood following caffeine
supplementation despite a poor night of sleep. In a study evaluating caffeine
supplementation following sleep deprivation, there was a 33% decrease in fatigue and a
55% increase in vigor as assessed by the POMS survey (53). Additionally, supplementation
with 300 mg of caffeine decreased fatigue by 6% and increased vigor by 39% following
72 hours of sleep deprivation in Navy Seal trainees (36). The noted improvements in mood
following caffeine supplementation supports previous knowledge that caffeine exerts its
ergogenic properties through influence on the central nervous system and ratings of
perceived exertion (34). Altogether, these findings suggest that caffeine ingestion is a
worthwhile strategy to compensate for probable impairments in performance following a
night of SR.
In addition to observed alterations in time trial performance and mood,
cardiorespiratory variables during submaximal exercise (fixed-load phase) seemed to be
affected by sleep condition and caffeine supplementation. This observation is contradictory
to our previous study which lacked any sleep-related alterations in physiological responses
to steady state exercise (13). The SR/CAF condition increased ventilation, VO2, and HR.

39

Considering there were modest changes in these variables in the SR/PLA or FULL/CAF
conditions, we cannot attribute these findings to sleep restriction or caffeine
supplementation alone. Sleep restriction and caffeine supplementation have been
separately implicated with increasing levels of catecholamine levels, which could have
secondary influences on these cardiorespiratory variables (23, 42, 57). Although these
changes were present, it is important to note that cardiorespiratory variables were assessed
during submaximal exercise, whereas time trial performance was by nature, higher in
intensity.
Based on the current findings, there is uncertainty surrounding the effects of sleep
restriction on recovery from heavy exercise. While some research suggests that sleep
restriction impedes recovery compared to a full night of sleep, the present study did not.
Regardless, there were performance decrements the following morning that were
compensated for following supplementation with caffeine. This further strengthens the
well-established role caffeine plays as an ergogenic aid. While there were mood
disturbances following sleep restriction that were improved following caffeine
supplementation, it is not likely that mood was the only factor contributing to decreased
morning performance. Perhaps negative expectations, or a ‘nocebo’ effect, contributed to
the poor time trial performance in the morning trials in the placebo treatment. These
findings necessitate further research considering the conflicting results between recent
work done in our lab and the current findings regarding the effects of sleep restriction on
recovery from heavy exercise and next day performance. Specifically, more definitive
mechanisms are needed to determine why sleep restriction impairs recovery and next day
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performance. Finally, more research is warranted to determine the effects of time of day
on performance and the efficacy of caffeine supplementation following sleep restriction.
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Table 1. Subject Demographics
Age
VO2max (ml•kgPeak
Height
Body Mass
1•min-1)
(yrs)
Watts
(cm)
(kg)
Subjects
21.3 ±
60.7± 8.0
290 ± 47 174.6 ± 7.0
69.8 ± 7.6
(n=10)
2.9
Data are expressed as means ± SD. Peak Watts represents power output at final complete
stage of VO2max test
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Table 2. Sleep Data
Sleep Onset Time

Wake-Up Time

Sleep Duration (hrs)

Efficiency (%)

FULL/PLA

10:46 PM
(9:35PM-12:38AM)

6:06 AM
(5:25-7:00AM)

6:28
(5:28-7:09)

88
(70-93)

SR/PLA

10:57 PM
(9:52PM-12:40AM)

2:27 AM
(1:30-3:40AM)

3:00
(2:23-3:31)

85
(69-100)

SR/CAF

10:54 PM
(9:57PM-12:38AM)

2:27 AM
(1:30-3:31AM)

3:06
(2:16-3:57)

88
(68-96)

FULL/CAF

10:45 PM
(9:37PM-12:40AM)

5:59 AM
(4:55-6:50AM)

6:19
(5:37-7:16)

87
(75-96)

Data are expressed as means with ranges displayed below. FULL, full night of sleep; SR, sleep restriction; CAF, caffeine
treatment; PLA, placebo treatment. Regardless of treatment, participants fasted from caffeine at least 24 hours before beginning
the evening exercise session. Sleep efficiency is a measure of sleep quality ([time in bed ˗ sleep latency ˗ time awake/time in
bed], with 85% being considered sufficient.
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Table 3. Peak Torque, Total Work, and Fatigue Index
Peak Torque
120 deg∙sec-1 (Nm)

Total Work (J)

Fatigue Index (%)

FULL/PLA

164 ± 35

6020 ± 1548

31.0 ± 4.1b

SR/PLA

163 ± 29

5920 ± 1726

25.7 ± 5.0

SR/CAF

164 ± 36

6105 ± 1351a

29.6 ± 6.4

FULL/CAF

166 ± 26

6366 ± 1552

32.9 ± 6.4

Data are expressed as means ± SD. To assess fatigue index, participants performed 30 isokinetic leg
extensions on the Biodex at 120 deg∙sec-1. All values are representative of morning exercise sessions; a,
‘possibly’ higher than SR/PLA [53% LH]; b, ‘very likely’ higher than SR/PLA [97% LH].

44

Table 4. Profile of Mood States (POMS)
Total Mood Disturbance

Fatigue-Inertia

Vigor-Activity

FULL/PLA

41 ± 5a,b

42 ± 5.2

43.4 ± 10.1

SR/PLA

44 ± 6c

46.9 ± 8e,f

40.1 ± 9.1h

SR/CAF

43 ± 6

42.8 ± 5.6g

47.4 ± 10.2i,j

FULL/CAF

40 ± 5d

40.3 ± 5.2

49.5 ± 10.3

Data are expressed as means ± SD. Total mood disturbance was assessed using the POMS questionnaire, which
investigates transient mood states; a, ‘likely’ lower than SR/PLA [95% LH]; b, ‘likely’ lower [83% LH] than SR/CAF;
c ‘possibly’ greater [53% LH] than SR/CAF; d ‘very likely’ lower [98% LH] than SR/CAF; e, ‘very likely’ greater
[92% LH] than FULL/PLA; f, ‘very likely’ greater [95% LH] than SR/CAF; g, ‘likely’ greater [79% LH] than
FULL/CAF; h, ‘possibly’ lower [72% LH] than FULL/PLA; i, ‘likely’ greater [93% LH] compared to SR/PLA; j,
‘possibly’ lower [45% LH] than FULL/CAF
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Table 5. Responses to Fixed-Load Exercise
Steady State HR
RPE
VO2 (mL/kg/min)
Ventilation
RER
(bpm)
(L/min)
FULL/PLA
153 ± 14a
12.5 ± 1.3f
40.9 ± 3.1b
72.5 ± 7.2d
0.86 ± 0.04e
f
c
d
SR/PLA
155 ± 19
12.7 ± 1.6
41.6 ± 4.9
73.0 ± 9.7
0.87 ± 0.04
SR/CAF
156 ± 15
11.8 ± 1.1
43.1 ± 4.1
77.0 ±8.9
0.87 ± 0.05
FULL/CAF
152 ± 15a
12.6 ± 1.3f
42.1 ± 2.5c
75.9 ± 9.2e
0.85 ± 0.03
Data are expressed as means ± SD. a, ‘possibly’ lower than SR/CAF [FULL/CAF, 55% LH; FULL/PLA, 58% LH]; b, ‘likely’
lower than SR/CAF [86% LH]; c, ‘possibly’ lower than SR/CAF [SR/PLA, 70% LH; FULL/CAF, 50% LH];
d, ‘likely’ lower than SR/CAF [FULL/PLA, 94% LH; SR/PLA, 88% LH]; e, ‘possibly’ lower than SR/CAF [ventilation, 63%
LH; RER, 61% LH]; f, ‘very likely’ higher than SR/CAF [FULL/PLA, 98% LH; SR/PLA, 99% LH; SR/CAF, 96% L
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Figure 1. Experimental Design

FULL
Evening
EX1

Morning
EX2
SR

PLA
CAF
3-km TT
20-min
20 min
Biodex
Biodex
Fixed-load
Fixed-load (~5 min)
PLA
SR
CAF
Figure 1. Experimental design and primary dependent measures. Sleep+, full night of sleep; Sleep-, night of sleep
restriction; PLA, placebo treatment one hour before commencing EX2; CAF, caffeine treatment before commencing EX2.
3-km TT
(~5 min)

60 min
Intervals

FULL
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Figure 2. 3-km Time Trial Performance Power Output

FULL/PLA

SR/PLA

SR/CAF

FULL/CAF

350
EX1 PWR
c
b

3-KM TT Power (Watts)

300

a
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Figure 2. Mean power output in the morning following condition and treatment. SR/PLA,
sleep restriction and placebo; SR/CAF, sleep restriction and caffeine; FULL/CAF, full
night of sleep and caffeine; FULL/PLA, full night of sleep and placebo. The dashed
horizontal line represents the average power output for the 3-km time trial in EX1, which
was 273.7 ± 69.2 W; a, ‘possibly’ greater than FULL/PLA (0.9 ± 3.6%; 44% LH); b,
‘likely’ greater than SR/PLA (5.5 ± 4.8%; 94%); c, ‘very likely’ higher than FULL/PLA
(6.5 ± 5.2%; 96% LH).
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Appendices
James Madison University
Department of Kinesiology
Consent for Investigative Procedure

I, ______________________, hereby agree on _____________ (date) to participate in the
research project conducted by Nicholas D. Luden, Ph.D. and Erin Horil from James
Madison University titled Performance Impairment Following Sleep Restriction - Is
Caffeine the Antidote?
The purpose of this study is to determine the effects caffeine has on performance following
recovery from exercise following sleep restriction. Additionally, this study aims to
determine the effects that caffeine has on performance following heavy exercise, compared
to a full night of rest without caffeine.
Subject Responsibility
I understand that I will undergo the following testing:
This study consists of 11 separate visits performed, 10 of which will involve exercise on a
resistance exercise device and 10 of which will involve exercise on a stationary bike
(cardiovascular fitness test, two familiarization trials, and six exercise trials). All testing
will occur in Godwin Hall, room 209, on the campus of James Madison University. You
will also be asked about lifestyle behaviors such as smoking and physical activity and
complete dietary and physical activity records. The total time commitment is estimated to
be less than 16 hours over the course of 6 weeks.
Preliminary Trial (1 visit; 60 min):
After completing this consent form and the health history screening, if you meet the
inclusion criteria for the study, researchers will measure your height and body weight.
You will then be asked to perform a maximal cardiovascular fitness test to determine your
maximum oxygen consumption (VO2max). You will be asked to ride a stationary bike at an
initial workload that is ‘fairly easy’. The workload will then be increased every two minutes
until fatigue is reached, determined by either: 1) your request to stop due to fatigue, or 2)
inability to maintain a cadence of ≥50 revolutions per minute. You will be verbally
encouraged to continue to obtain an accurate measurement of VO2max. To access oxygen
consumption, you will need to breathe through a mouthpiece/breathing apparatus which
collects expired air throughout the test (10-15 minutes).
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Familiarization Phase (2 visits; total time of 180 min):
The familiarization phase will consist of two consecutive days of exercise trials. Procedures
will be the same as the experimental trials detailed below. However, no blood samples will
be obtained and you will not be assigned to sleep and caffeine conditions.
Experimental Phase
Exercise Trial 1 (4, 120 min each)
You will be asked to arrive at the human performance lab between 3-5pm, not having
consumed alcohol, tobacco or caffeine 24 hrs prior to testing.
Muscle Soreness – Upon arriving to the lab, you will be asked to rate your level of muscle
soreness using a scale ranging from 0-100 (taken walking up stairs, walking down stairs
and standing) and subjective ratings of energy and fatigue will be assessed using a short
questionnaire.
3-km Cycling Time Trial – Immediately following the questionnaires, you will be prompted
to perform a 20-min warm-up on a stationary cycle ergometer. During the warm-up, several
measurements will be taken (detailed below). Following the warm-up, you will be
prompted to transition into a 3-km computer-simulated time trial on the cycle ergometer.
This will last approximately 4-7 minutes and you will be reminded to treat this like a
competition.
Skeletal Muscle Function – 10 minutes following the 3-km cycling time trial, you will
perform a muscle strength test where you will be asked to push as hard as possible against
a shin pad for 30 consecutive leg extensions.
60-minute Sprint Interval – Immediately following completion of the skeletal muscle
function testing, you will complete 60 min of sprint intervals. You will only perform these
intervals on Exercise Trial 1. You will be asked to cycle at high intensities for 2-minute
intervals, separated by 2 min of moderate intensity cycling. Intensity will be progressively
decreased throughout to permit you to finish the 60-minute session.
Exercise Trial 2 (4, 60 min each)
You will be asked to arrive at the human performance lab between 7-9 am, not having
consumed alcohol, tobacco, or caffeine 24 hrs prior to testing.
Muscle Soreness – Upon arriving to the lab, you will be asked to rate your level of muscle
soreness using a scale ranging from 0-100 (taken while walking up stairs, walking down
stairs, and standing) and subjective ratings of energy and fatigue will be assessed using a
short questionnaire.
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3-km Cycling Time Trial – You will then be asked perform a 20-min warm-up on a
stationary cycle ergometer, then perform a 3-km computer-simulated time trial on the cycle
ergometer. This will last approximately 4-7 minutes.
Skeletal Muscle Function – 10 minutes following the 3-km cycling time trial, you will
again perform 30 consecutive leg extensions on the resistance exercise device as described
above.
Measurements During 20-Minute Warm-Up
Heart Rate & Rate of Perceived Exertion (HR & RPE)
You will be fitted for a heart rate monitor so that we can measure your heart rate throughout
the exercise trial. Additionally, you will be asked to rate your level of exertion on a scale
from 6 to 20 at various points throughout your warm up.
Glucose & Lactate (GLU & LAC)
Finger-stick blood samples (1-2 drops of blood) will be obtained at min 10 and min 20 of
the warm-up preceding the 3km time trial for measurement of blood sugar and lactic acid.
Oxygen Consumption, Ventilation, & Respiratory Exchange Ratio (VO2, VE &
RER)
You will also be hooked up to a mouth-piece (and nose clip) in 2 x 5-minute increments
during the warm-up for measurement of oxygen consumption and other measures of
cardiorespiratory function.
Sleep Protocol:
Sleep will be measured, but not controlled, during the familiarization trials. During the
experimental phases, you will be randomly assigned to a sleep and caffeine condition: a
full night of sleep with placebo, a full night of sleep with caffeine, a night of sleep
restriction with placebo, or a night of sleep restriction with caffeine. You will either be
given a caffeine pill or placebo pill filled with rice flour, but you will not know which
treatment you are receiving. You will not know your assigned sleep condition until
completion of the first exercise trial. The sleep condition will be randomly selected for
each exercise phase such that you may be assigned each sleep condition, or multiples of
the same sleep/caffeine conditions. Following the first night of sleep assignment, you will
be asked to record what you wore to sleep and replicate that on the second night of sleep
assignment. You will also be asked to download a smartphone application, Sleep Cycle,
which will detect movement during sleep, and wake up either 3.5 or 7.5 hrs following sleep
onset, dependent upon sleep assignment for the night. Finally, you will wear an
accelerometer to record movements while you sleep. Should you not comply with sleep
protocols, you will be given another chance to complete the study seven days later. Failure
to comply with sleep protocol a second time will result in removal from the study.
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Caffeine Treatment:
Caffeine pills will be prepared for you individually. The caffeine treatment will consist of
6mg caffeine powder per kilogram body weight. Placebo pills will be filled with rice
flour. You will be prompted to consume the treatment pill one hour before your visit for
EX 2. You will not know the treatment you are receiving at any time during the study. At
the conclusion of the study, you will be asked to guess which treatment you received for
each condition.
Dietary and Exercise Controls:
You will be asked to record all food and beverage intake for 24 hrs preceding the first
exercise trial and the day of EX 2. After the initial exercise trial, you will be provided with
copies of your dietary records and instructed to replicate their dietary habits for the second
EX phase. You will be asked to report to all testing after a >2 hr fast. You will be asked to
consume Ensure Active High Protein Shake within 1 hour of completing the first exercise
trial. Additionally, you will be instructed to refrain from consuming anything other than
water during the 2 hours following EX1. You will be asked to record of dietary intake
following EX1, and replicate that seven days later after the second EX1 trial, and seven
days after that for the third EX1 trial. For all conditions, you will be given a standardized
breakfast to consume two hours before beginning EX2. You will also be instructed to
record all physical activity 72 hrs prior to the first exercise trial in all phases and the day
of EX 2. Additionally, you will be instructed to avoid physical activity between the first
and second exercise trials, and to keep physical activity habits consistent between all
exercise phases.
Risks/Benefits:
Skeletal Muscle Function
The risks of muscle function testing include soreness from exertion 24-48 hours post and
potential lightheadedness or loss of consciousness if correct form is not utilized. You will
be instructed in correct form and breathing techniques prior to testing.
Sleep Disruption
The consequences of a single night of sleep restriction comparable to this investigation
have not been well documented but include impaired insulin sensitivity, increased
sleepiness and fatigue, and reduced alertness and constant attentiveness. The latter have
the potential to impact short-term academic performance, decision-making and tasks such
as driving ability but these have not been documented.

Cardiovascular Exercise (3-km Time Trial, 60-min sprint interval session, and VO2max test)
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According to the American College of Sports Medicine’s Guidelines for Exercise Testing
and Prescription, the risk associated with heavy exercise for individuals categorized as
“low risk” is very minimal, and physician supervision is not necessary. The conditions that
the exercise sessions are to take place are likely safer than the typical exercise environments
of the subjects. If you do not meet ACSM criteria for “low risk”, you will not be allowed
to participate in the study. In the unlikely event of cardiac or other complications during
exercise, an emergency plan is in place. This includes immediate access to a phone to call
emergency personnel. In addition, at least one of the listed investigators will be present
during the exercise sessions, and all are CPR certified.
Caffeine Ingestion
The risks and side effects associated with caffeine supplementation include: rapid heart
rate, elevated blood pressure, headache, nausea, vomiting, restlessness, agitation, and
anxiety.
Blood Sampling
The risks of finger-stick blood sampling include possible mild bruising, and the risk of
transfer of blood-borne pathogens, as well as possible risks of infection or skin irritation.
These risks are considered to be minimal, and all safety precautions for handing blood
samples will be followed according to OSHA protocols, including: investigators will wear
latex gloves at all times during blood sampling and testing. A sharps container lined with
a biohazard bag will be used for all sharp objects involved in the blood sampling; all other
materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in a separate
waste disposal unit lined with a biohazard bag. All investigators who will be involved in
blood draws (and handling of blood) have been trained in these phlebotomy techniques,
and completed JMU blood-borne pathogen training. A total of <10 milliliters of blood will
be obtained throughout the course of the study, which is roughly 2% of the amount of blood
typically obtained during blood donation (1 pint or 473 milliliters)
Performance incentive:
The top 5 3-km time trial performers will be entered into a drawing to win $150. Individuals
with the top 6-10 times will be entered into a drawing to win $75. Times from both EX2
trials will be averaged to determine the top performers.
Confidentiality:
The results of this research will be presented at conferences and published in exercise
science journals. The results of this project will be coded in such a way that your identity
will not be attached to the final form of this study. The researcher retains the right to use
and publish non-identifiable data. However, you can ask that your data be removed from
the study at any point prior to presentation and publication. While individual responses
are confidential, aggregate data will be presented representing averages or generalizations
about the responses as a whole. All data will be stored in a secure location accessible only
to the researcher. Final aggregate results will be made available to you upon request.
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Participation & Withdrawal:
Your participation is entirely voluntary. You are free to choose not to participate. Should
you choose to participate, you can withdraw at any time without consequences of any kind.
Your right to withdraw includes the right to request that your blood samples be discarded
at any time. To dispose of your samples, your samples will be rinsed down a chemical drain
in our laboratory or will be disposed of in a biohazard container. Again, your sample will
not be identifiable without the coding document that will be locked away in a filing cabinet.
Questions:
You may have questions or concerns during the time of your participation in this study, or
after its completion. If you have any questions about the study, contact Nicholas D. Luden,
Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068.

Giving of Consent:
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I certify
that I am at least 18 years of age.

Name of Participant (Printed)

Name of Researcher(s) (Printed)

Name of Participant (Signed)

Name of Researcher(s) (Signed)

Date

Date

For questions about your rights as a research subject, you may contact the chair of JMU’s
Institutional Review Board (IRB).
Dr. David Cockley, (540) 568-2834,
cocklede@jmu.edu.
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AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
Assess your health status by marking all true statements
______________________________________________________________________________________
History
You have had:
a heart attack
heart surgery
cardiac catheterization
coronary angioplasty (PTCA)
pacemaker/implantable cardiac
defibrillator/rhythm disturbance
heart valve disease
heart failure
heart transplantation
congenital heart disease

If you marked any of these
statements in this section, consult
your physician or other appropriate
health care provider before engaging
in exercise. You may need to use a
facility with a medically qualified
staff.

Symptoms
You experience chest discomfort with exertion
You experience unreasonable breathlessness
You experience dizziness, fainting, or blackouts
You take heart medications
Other Health Issues
You have diabetes
You have asthma or other lung disease
You have burning or cramping sensation in your lower legs when walking short distances
You have musculoskeletal problems that limit your physical activity
You have concerns about the safety of exercise
You take prescription medication(s)
______________________________________________________________________________
Cardiovascular risk factors
If you marked two or more of the
You are a man older than 45 years
statements in this section, you should
You smoke, or quit smoking within the
consult your physician or other
previous 6 months
appropriate health care provider
Your blood pressure is > 140/90 mmHg
before engaging in exercise. You
You do not know your blood pressure
You take blood pressure medication
might benefit from using a facility
Your blood cholesterol level is > 200 mg/dl
with a professionally qualified
You do not know your cholesterol level
exercise staff to guide your exercise
You have a close blood relative who
program.
had a heart attack or heart surgery before age
55 (father or brother) or age 65 (mother or sister)
You are physically inactive (i.e. you get
< 30 minutes of physical activity on at least 3 days of the week)
You are > 20 pounds overweight
______________________________________________________________________________________

None of the above

You should be able to exercise safely
without consulting your physician or
other appropriate health care
provider in a self-guided program or
almost any facility that meets your
exercise program needs.
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The Pittsburgh Sleep Quality Index (PSQI)
Instructions: The following questions relate to your usual sleep habits during the past month only. Your answers
should indicate the most accurate reply for the majority of days and nights in the past month. Please answer all
questions. During the past month,
1. When have you usually gone to bed? ______________
2. How long (in minutes) has it taken you to fall asleep each night? ______________
3. When have you usually gotten up in the morning? ______________
4. How many hours of actual sleep do you get at night? (This may be different than the number of hours you
spend in bed) ______________
5. During the past month, how often have you Not during
Less than
Once or
Three or
had trouble sleeping because you…

the past
month (0)

once a
week (1)

Very
good (0)

Fairly
good (1)

twice a more times
week (2) week (3)

a. Cannot get to sleep within 30 minutes
b. Wake up in the middle of the night or early
morning
c. Have to get up to use the bathroom
d. Cannot breathe comfortably
e. Cough or snore loudly
f. Feel too cold
g. Feel too hot
h. Have bad dreams
i. Have pain
j. Other reason(s), please describe,
including how often you have had trouble
sleeping because of this reason(s):
6. During the past month, how often have you
taken medicine (prescribed or “over the
counter”) to help you sleep?
7. During the past month, how often have
you had trouble staying awake while driving,
eating meals, or engaging in social activity?
8. During the past month, how much of a
problem has it been for you to keep up
enthusiasm to get things done?
Fairly
bad (2)

Very
bad (3)

9. During the past month, how would
you rate your sleep quality overall?
Component 1
Component 2
Component 3
Component 4
Component 5
Component 6

#9 Score ....................................................................................................... C1_______
#2 Score (≤15min=0; 16-30 min=1; 31-60 min=2, >60 min=3) + #5a Score (if sum
is equal 0=0; 1-2=1; 3-4=2; 5-6=3) .............................................................. C2_______
#4 Score (>7=0; 6-7=1; 5-6=2; <5=3) .......................................................... C3_______
(total # of hours asleep)/(total # of hours in bed) x 100
>85%=0, 75%-84%=1, 65%-74%=2, <65%=3 ............................................. C4_______
Sum of Scores #5b to #5j (0=0; 1-9=1; 10-18=2; 19-27=3).......................... C5_______
#6 Score ........................................................................................................ C6_______
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Component 7

#7 Score + #8 Score (0=0; 1-2=1; 3-4=2; 5-6=3)........................................... C7_______
Add the seven component scores together ________ Global PSQI Score ________

Buysse, D.J., Reynolds III, C.F., Monk, T.H., Berman, S.R., & Kupfer, D.J. (1989). The Pittsburgh Sleep Quality Index: A new
instrument for psychiatric practice and research. Journal of Psychiatric Research, 28(2), 193-213.
Reprinted with permission from copyright holder for educational purposes per the University of Pittsburgh, Sleep Medicine Institute,
Pittsburgh Sleep Quality Index (PSQI) website at http://www.sleep.pitt.edu/content.asp?id=1484&subid=2316.

60

Daily Activity Records
Subject #

Date

Date:_____________
Type of Exercise
Performed

Intensity Scale
6
7
Very, very light
8
9
Very light
10
11
Fairly light
12
13
Somewhat hard
14
15
Hard
16
17
Very hard
18
19
Very, very hard
20

Duration of
Exercise
(minutes)

Intensity of
Exercise
(use scale below)
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DIET RECORD
Subject number____________
Week______________

Time Food and/or
Drink

Method of
Preparation

Date______________

Quantity
Consumed

Day of

Brand Name

Adapted From: Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of
America: Mosby; 1996.
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Subject Prescreening Information

Age:

years

Height

Weight

_

Typical Exercise Habits over the Past 3-6 Months:

Average number of days of cycling per week
Average number of hours of cycling per week
Briefly describe your cycling habits over the past 3-6 months:
Average number of days of resistance exercise/weight lifting per week
_____________
Average number of days of resistance exercise/weight lifting per week
_____________
Briefly describe your resistance training habits over the past 3-6 months:

Do you have a muscle or joint injury/condition that precludes the completion of the
cycling or muscle function protocol? If yes, please explain.

Are you allergic to wheat?

Do you have gluten intolerance?

Are you allergic to latex?
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